share_log

The Worldwide Assisted Reproductive Technology Industry is Expected to Reach $12 + Billion by 2030 - ResearchAndMarkets.com

The Worldwide Assisted Reproductive Technology Industry is Expected to Reach $12 + Billion by 2030 - ResearchAndMarkets.com

全球輔助生殖技術產業到2030年有望達到120多億美元--Research andMarkets網站
Businesswire ·  2021/11/18 01:00

DUBLIN--(BUSINESS WIRE)--The "Assisted Reproductive Technology Market by Product, Technology, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

都柏林--(美國商業資訊)--《按產品、技術和最終用户劃分的輔助生殖技術市場:2021-2030年全球機遇分析和行業預測》報告已被添加到Research andMarkets.com的獻祭。


The global assisted reproductive technology market was valued at $2,317.7 million in 2020, and is estimated to reach $12,272.5 million by 2030, growing at a CAGR of 19.3% from 2021 to 2030.

全球輔助生殖技術市場在2020年價值23.177億美元,預計到2030年將達到122.725億美元,從2021年到2030年以19.3%的複合年增長率增長。

Assisted reproductive technology (ART) is defined as the medical procedure used to address the infertility treatments for handling of eggs and embryo. This technique aims to remove the eggs from a woman's ovaries and further combine it with sperm in the in-vitro laboratory condition. After fertilization, the egg or embryo is transferred to the uterus of women. It alleviates the burden of infertility on a family and individual. In-vitro technology is one of the most common and advanced procedures, which are used for the infertility treatment. The ART includes gamete intrafallopian transfer (GIFT), frozen embryo transfer (FET), zygote intrafallopian transfer and in vitro fertilization-embryo transfer.

輔助生殖技術(ART)被定義為用於處理卵子和胚胎的不孕症治療的醫療程序。這項技術旨在將卵子從女性卵巢中取出,並在體外實驗室條件下將其與精子進一步結合。受精後,卵子或胚胎被轉移到女性的子宮。它減輕了家庭和個人的不孕不育負擔。體外技術是治療不孕症最常用、最先進的方法之一。ART包括配子輸卵管內移植(GIFT)、冷凍胚胎移植(FET)、受精卵輸卵管內移植和體外受精-胚胎移植。

The global assisted reproductive technology market is majorly driven by an alarming increase in the prevalence of polycystic ovary syndrome, rise in disposable income, surge in demand for in vitro-fertilization, advancement in the technology for novel ART, and a rise in awareness about IVF and surrogacy. According to Office on Women's Health (OWH), in 2019, it was reported that 1 in 10 women of childbearing age are diagnosed with PCOS, in the U.S. According to Center for Disease control and Prevention (CDC), it was reported that 6% to 12% of the U.S. women of reproductive age, having PCOS, were also diagnosed with infertility.

全球輔助生殖技術市場的主要驅動因素是多囊卵巢綜合徵患病率的驚人增長、可支配收入的增加、體外受精需求的激增、新技術的進步以及對試管受精和代孕的認識的提高。根據婦女健康辦公室(OWH)的數據,2019年,據報道,美國每10名育齡婦女中就有1人被診斷出患有多囊卵巢綜合徵,根據疾病控制和預防中心(CDC)的數據,有6%到12%的美國育齡婦女也被診斷為患有多囊卵巢綜合徵。

PCOS is one of the most common causes of female infertility, which surge the demand for assisted reproductive technology and drive the growth of the market. The rise in disposable income has assisted reproductive technology and drives the growth of the market. Furthermore, in February 2021, TMRW Life Sciences, announced the launch of the world's first automated Cryo specimen management solution for eggs and embryo, which are used in the IVF procedure. The TMRW platform is introduced in various fertility clinics in the U.S. launching the software enables management of the million embryos and eggs central to modern IVF.

多囊卵巢綜合徵是女性不孕不育最常見的原因之一,它激增了對輔助生殖技術的需求,並推動了市場的增長。可支配收入的增加幫助了生殖技術,並推動了市場的增長。此外,2021年2月,TMRW生命科學公司宣佈推出世界上第一個用於試管受精程序的卵子和胚胎的自動冷凍標本管理解決方案。TMRW平臺被引入美國的各種生育診所,推出該軟件後,可以管理現代試管受精所需的數百萬個胚胎和卵子。

Increase in incidence of infertility cases and the surge in sedentary lifestyle are the major factors that drive the global assisted reproductive technology market. Moreover, the increase in prevalence of obesity significantly contributes toward the market growth, owing to obese person being more prone to infertility and uterine disorder. Rise in demand for in-vitro fertilization for effective treatment, and high success rate acts a key driving force of the global market.

不孕症發病率的增加和久坐不動的生活方式是推動全球輔助生殖技術市場的主要因素。此外,肥胖患病率的增加對市場增長有顯著貢獻,因為肥胖者更容易不孕和子宮紊亂。用於有效治療的體外受精需求上升,高成功率是全球市場的關鍵驅動力。

Furthermore, governments are taking multiple initiatives to support healthcare information systems for development of advanced ART, which is expected to boost the market growth. As per a study by the American Society for reproductive medicines, it was reported that approximately 40% of infertile couple, the male partner is responsible for infertility and among them 85% to 90% are treated with surgery. In addition, technological advancements in assisted reproductive technology, and growth in number of fertility clinic are anticipated to provide lucrative opportunities for the market expansion. The rise in awareness regarding cost-effective treatment of infertility and spread of knowledge about the success rate of IVF procedure propels the growth of the market.

此外,各國政府正在採取多種舉措,支持醫療保健信息系統開發先進的抗逆轉錄病毒治療,預計這將推動市場增長。根據美國生殖醫學學會的一項研究,據報道,大約40%的不孕夫婦,男性伴侶是不孕不育的罪魁禍首,其中85%至90%的人接受了手術治療。此外,輔助生殖技術的技術進步以及生育診所數量的增長預計將為市場擴張提供有利可圖的機會。人們對不孕不育治療成本效益的認識的提高,以及對試管受精程序成功率的瞭解的傳播,推動了市場的增長。

On the contrary, risk associated after IVF procedure and high cost of assisted reproductive technology are anticipated to hinder the market growth during the forecast period. The rise in number of fertility clinic and development of IVD devices leads to the enhancement of the assisted reproductive technology sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the assisted reproductive technology market.

相反,預計試管受精手術後的相關風險和輔助生殖技術的高昂成本將在預測期內阻礙市場增長。生育診所數量的增加和IVD設備的開發導致輔助生殖技術部門得到加強。這鼓勵了許多關鍵參與者進入新興市場,從而在輔助生殖技術市場提供了一個有利可圖的增長機會。

Key Benefits

主要優勢

  • The report provides an in-depth analysis of the global assisted reproductive technology market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global assisted reproductive technology market.
  • 該報告深入分析了全球輔助生殖技術的市場規模,以及當前的趨勢和未來的估計,以闡明迫在眉睫的投資口袋。
  • 它提供了從2021年到2030年的市場分析,預計將使利益攸關方能夠利用市場上的主要機會。
  • 對區域的全面分析有助於瞭解區域市場,促進戰略業務規劃和確定當前的機遇。
  • 深入分析了主要參與者的概況和增長戰略,以瞭解全球輔助生殖技術市場的競爭前景。

Market Dynamics

市場動態

Drivers

司機

  • Increase in prevalence of infertility rate
  • Technological advancements in assisted reproductive technology
  • Growth in disposable income and rise in awareness regarding infertility treatment
  • 不孕不育率上升
  • 輔助生殖技術的技術進展
  • 可支配收入的增長和不孕不育治療意識的提高

Restraint

剋制

  • High cost of ART procedure
  • Risk associated with IVF treatment
  • ART程序的高成本
  • 試管受精治療的相關風險

Opportunity

機會

  • Growing opportunities in emerging market and rise in fertility tourism
  • 新興市場的機會越來越多,生育旅遊興起

Companies Mentioned

提到的公司

  • Cook Medical Inc.
  • Fujifilm Holdings Corporation (Irvine Scientific Sales Company Inc.)
  • Genea Biomedx
  • Merck KGaA (EMD Serono Inc.)
  • Millendo Therapeutics Inc.
  • Oxford Gene Technology
  • Progyny Inc.
  • The Cooper Companies Inc. (CooperSurgical Inc.)
  • Thermo Fisher Scientific, Inc.,
  • Vitrolife AB
  • 庫克醫療公司
  • 富士膠片控股公司(歐文科學銷售公司)
  • 吉尼亞生物醫藥公司
  • 默克KGaA(EMD Serono Inc.)
  • Millendo治療公司。
  • 牛津基因技術
  • Progyny Inc.
  • 庫珀公司(Coper Surgical Inc.)
  • Thermo Fisher Science,Inc.
  • Vitrolife AB

For more information about this report visit https://www.researchandmarkets.com/r/uywdru

欲瞭解更多有關本報告的信息,請訪問https://www.researchandmarkets.com/r/uywdru。


Contacts
聯繫人

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

ResearchAndMarkets.com
高級新聞經理勞拉·伍德
郵箱:Press@researchandMarkets.com
東部夏令時辦公時間請撥打1-917-300-0470
美國/加拿大免費電話:1-800-526-8630
對於格林尼治標準時間辦公時間,請致電+353-1-416-8900

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論